+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05732103

Phase 12 Study of CTX-712 Treatment for Adults with Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

Led by Chordia Therapeutics, Inc. · Updated on 2026-04-13

225

Participants Needed

8

Research Sites

35 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating CTX-712 in patients with relapsed or refractory acute myeloid leukemia AML and higher risk myelodysplastic syndromes HR-MDS, including MDSMPN such as CMML. This phase 12 multicenter, open-label study aims to assess the safety, tolerability, and how the drug behaves in the body, as well as its effects on RNA splicing. The study includes dose escalation and expansion to find the best dose and further evaluate therapeutic activity in these conditions. The study begins with phase 1 dose escalation using a standard 3 3 design, where patients receive increasing doses of CTX-712 once or twice weekly in 28-day cycles to identify the recommended phase 2 dose RP2D. After establishing the RP2D, expansion cohorts in AML and HR-MDS will receive CTX-712 at this dose. Additional cohorts may be added, including drug-drug interaction studies. Phase 2 will then evaluate the treatments activity and safety using the confirmed RP2D. Participants will be monitored closely through laboratory tests to assess organ function and blood counts. Safety is tracked by recording adverse events from consent through 28 days after the last dose. Pharmacokinetic and pharmacodynamic evaluations occur during treatment cycles, including blood sampling to study the drugs behavior and effects. The main outcomes measured include safety, maximum tolerated dose, complete remission rate, and other response and survival rates. Follow-up may continue up to 36 months to track long-term effects and transitions to stem cell transplantation.

CONDITIONS

Brief Title

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Research Team

L

Laurie F Graham, RN, MSN

H

Haris Durutlic

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here